Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
Abstract. Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. Al...
Main Authors: | Evangelos Terpos, Ioannis V. Kostopoulos, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Pantelis Rousakis, Alexandra T. Argyriou, Nikolaos Kanellias, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Dimitrios C. Ziogas, Aristea-Maria Papanota, Marilyn Spyropoulou-Vlachou, Ioannis P. Trougakos, Ourania E. Tsitsilonis, Bruno Paiva, Meletios A. Dimopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2019-12-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000300 |
Similar Items
-
Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome
by: Maria Gavriatopoulou, et al.
Published: (2020-06-01) -
Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients
by: Ioannis V. Kostopoulos, et al.
Published: (2021-08-01) -
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
by: Ioannis V. Kostopoulos, et al.
Published: (2020-05-01) -
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
by: Evangelos Terpos, et al.
Published: (2021-08-01) -
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
by: Evangelos Terpos, et al.
Published: (2020-10-01)